SIONNA THERAPEUTICS, INC.

EDGAR

Market value

$155.16M

45,235,568 shares as of 2026-10-30, at $3.43 a share (SION, IEX close on 2026-11-12) Primary-source evidence

11 filing records in this dataset, filed from 2025-01-17 to 2026-11-10. Reported financial figures are available; chart coverage varies by period.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Window: transactions dated on or after 2025-11-17.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
82 transactions, 6,366,228 shares
Sum of shares × price per share: 151,094,362.55

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

  • 2026-09-17 RA CAPITAL MANAGEMENT, L.P. S 3,415,011 6.32
  • 2026-09-17 RA CAPITAL MANAGEMENT, L.P. S 33,800 7.46
  • 2026-09-17 Fitzpatrick Jennifer A 28,133 0.0
  • 2026-09-17 Fitzpatrick Jennifer A 28,132 0.0
  • 2026-09-17 Fitzpatrick Jennifer A 103,140 0.0

5% holders (Schedule 13D and 13G)

  • THE GOLDMAN SACHS GROUP, INC. 5.8% SCHEDULE 13G 09/30/2026
  • GOLDMAN SACHS CO. LLC 5.8% SCHEDULE 13G 09/30/2026
  • RA Capital Management, L.P. 14.3% SCHEDULE 13D/A 09/17/2026

See all insider transactions

Cash and cash equivalents
83.9 million USD Source
Exact value

83878000 USD

Long-term debt including current maturities
Not available
Shares outstanding
45.2 million shares Source
Exact value

45214369 shares

Reported share-count change

1.69% · 751 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence
  • 44463527 shares · 2025-09-30· Source
  • 45214369 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-110 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Net income: -75268000 USD · 2025-01-01 – 2025-12-31 Source
  • Net income: -54828000 USD · 2025-01-01 – 2025-09-30 Source
  • Net income: -26779000 USD · 2026-01-01 – 2026-03-31 Source
  • Net income: -29886000 USD · 2026-04-01 – 2026-06-30 Source
  • Net income: -32418000 USD · 2026-07-01 – 2026-09-30 Source

Operating cash flow

-79.4 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Operating cash flow: -66297000 USD · 2025-01-01 – 2025-12-31 Source
  • Operating cash flow: -49671000 USD · 2025-01-01 – 2025-09-30 Source
  • Operating cash flow: -21840000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -44060000 USD · 2026-01-01 – 2026-06-30 Source
  • Operating cash flow: -21840000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -62783000 USD · 2026-01-01 – 2026-09-30 Source
  • Operating cash flow: -44060000 USD · 2026-01-01 – 2026-06-30 Source

Capital expenditure

204 thousand USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Capital expenditure: 377000 USD · 2025-01-01 – 2025-12-31 Source
  • Capital expenditure: 173000 USD · 2025-01-01 – 2025-09-30 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-09-30 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source

Free cash flow

-79.6 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Operating cash flow: -66297000 USD · 2025-01-01 – 2025-12-31 Source
  • Operating cash flow: -49671000 USD · 2025-01-01 – 2025-09-30 Source
  • Operating cash flow: -21840000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -44060000 USD · 2026-01-01 – 2026-06-30 Source
  • Operating cash flow: -21840000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -62783000 USD · 2026-01-01 – 2026-09-30 Source
  • Operating cash flow: -44060000 USD · 2026-01-01 – 2026-06-30 Source
  • Capital expenditure: 377000 USD · 2025-01-01 – 2025-12-31 Source
  • Capital expenditure: 173000 USD · 2025-01-01 – 2025-09-30 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-09-30 Source
  • Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-11-10.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 2 of 11 periods available· newest 2025-12-31
  • Net income: 2 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 2 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 2 of 11 periods available· newest 2025-12-31
  • Total assets: 2 of 11 periods available· newest 2025-12-31
  • Total liabilities: 2 of 11 periods available· newest 2025-12-31
  • Current assets: 2 of 11 periods available· newest 2025-12-31
  • Current liabilities: 2 of 11 periods available· newest 2025-12-31
  • Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
  • long term debt: No compatible figures in this window
  • Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    −USD 13.58 million

    Prior period

    −USD 61.69 million

    –

    Current period

    −USD 75.27 million

    –

    Exact inputs and evidence

    -75268000 − -61688000 = -13580000 USD

    -61688000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -75268000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    −USD 13.51 million

    Prior period

    −USD 52.79 million

    –

    Current period

    −USD 66.3 million

    –

    Exact inputs and evidence

    -66297000 − -52787000 = -13510000 USD

    -52787000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -66297000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    +1,296.3%

    Prior period

    USD 27,000

    –

    Current period

    USD 377,000

    –

    Exact inputs and evidence

    377000 − 27000 = 350000 USD

    27000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    377000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2024 2024-01-01 – 2024-12-31
−USD 61.69 million
Exact value

Exact value: -61688000 USD

2024-01-01 – 2024-12-31: -61688000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 52.79 million
Exact value

Exact value: -52787000 USD

2024-01-01 – 2024-12-31: -52787000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 27,000
Exact value

Exact value: 27000 USD

2024-01-01 – 2024-12-31: 27000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 52.81 million
Calculation and evidence

-52787000 − 27000 USD

Exact free cash flow: -52814000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2025 2025-01-01 – 2025-12-31
−USD 75.27 million
Exact value

Exact value: -75268000 USD

2025-01-01 – 2025-12-31: -75268000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 66.3 million
Exact value

Exact value: -66297000 USD

2025-01-01 – 2025-12-31: -66297000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 377,000
Exact value

Exact value: 377000 USD

2025-01-01 – 2025-12-31: 377000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 66.67 million
Calculation and evidence

-66297000 − 377000 USD

Exact free cash flow: -66674000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

11 filings · 556 latest values · 556 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0002036042, 2036042, SION, edgar:2036042

Also known as SIONNA THERAPEUTICS, INC., Sionna Therapeutics, Inc.